Objectives: To investigate the controversially discussed relationship between tumor size and the occurrence of primary synchronous metastatic disease in renal cell cancer (RCC). Patients and Methods: A consecutive RCC cohort of 2,058 patients (150 primary metastatic) who underwent surgery between 1995 and 2010 was investigated. Rates of synchronous metastases were calculated for stratified groups of tumor size. Uni- and multivariate logistic regression models were calculated for the correlation of tumor size with primary metastatic disease. Results: The rate of metastatic disease increased with increasing tumor size. Tumor size was significantly correlated with synchronous metastatic disease (p < 0.001, c-index 0.772), but for RCCs ≤4 cm in size no significant correlation was found. Regarding tumors ≤5 cm in size, the correlation became significant (p = 0.028, c-index 0.621). A multivariate logistic regression model for the prediction of synchronous metastatic disease including tumor size, age and comorbidity yielded a significant c-index of 0.82 and was used to construct a nomogram. Conclusion: Our data confirm the correlation between tumor size and the rate of synchronous metastatic disease. Small renal tumors <4 cm in size have a low risk of synchronous metastatic disease. The risk becomes significantly associated with tumor size for tumors ≤5 cm.

Keywords:
Renal cell cancer, Tumor size, Metastasis, Staging, Management
1.
Hock LM, Lynch J, Balaji KC: Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002;167:57-60.
2.
Kunkle DA, Crispen PL, Li T, Uzzo RG: Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 2007;177:1692-1696; discussion 1697.
3.
Lughezzani G, Jeldres C, Isbarn H, Perrotte P, Shariat SF, Sun M, Widmer H, Arjane P, Peloquin F, Pharand D, Patard JJ, Graefen M, Montorsi F, Karakiewicz PI: Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009;182:1287-1293.
4.
Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, Bernstein M, Coleman J, Dalbagni G, Touijer K, Russo P: Metastatic renal cell carcinoma risk according to tumor size. J Urol 2009;182:41-45.
5.
Klatte T, Patard J, Demartino M, Bensalah K, Verhoest G, Delataille A, Abbou C, Allhoff E, Carrieri G, Riggs S: Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol 2008;179:1719-1726.
6.
Larson DB, Johnson LW, Schnell BM, Salisbury SR, Forman HP: National trends in CT use in the emergency department: 1995-2007. Radiology 2011;258:164-173.
7.
Berland LL, Silverman SG, Gore RM, Mayo-Smith WW, Megibow AJ, Yee J, Brink JA, Baker ME, Federle MP, Foley WD, Francis IR, Herts BR, Israel GM, Krinsky G, Platt JF, Shuman WP, Taylor AJ: Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010;7:754-773.
8.
Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, Kirkali Z, Marberger M, Patard JJ, Staehler M, Uzzo RG: Contemporary management of small renal masses. Eur Urol 2011;60:501-515.
9.
Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
10.
Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED: Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008;113:450-460.
11.
Bedke J, Pritsch M, Buse S, Jakobi H, Elsaesser K, Pahernik S, Haferkamp A, Hohenfellner M: Prognostic stratification of localized renal cell carcinoma by tumor size. J Urol 2008;180:62-67.
12.
Karakiewicz P, Lewinshtein D, Chun F, Briganti A, Guille F, Perrotte P, Lobel B, Ficarra V, Artibani W, Cindolo L: Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol 2006;50:521-529.
13.
Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG: Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012;118:997-1006.
14.
Haramis G, Mues AC, Rosales JC, Okhunov Z, Lanzac AP, Badani K, Gupta M, Benson MC, Mckiernan J, Landman J: Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years. Urology 2011;77:787-791.
15.
Pahernik S, Ziegler S, Roos F, Melchior SW, Thüroff JW: Small renal tumors: correlation of clinical and pathological features with tumor size. J Urol 2007;178:414-416; discussion 416-417.
16.
Galfano A, Novara G, Iafrate M, Cavalleri S, Martignoni G, Gardiman M, D'Elia C, Patard JJ, Artibani W, Ficarra V: Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 2008;80:113-123.
17.
Bukowski RM, Negrier S, Elson P: Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004;10(18 Pt 2):6310S-6314S.
18.
Motzer RJ, Bacik J, Mazumdar M: Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004;10(18 Pt 2):6302S-6303S.
19.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
20.
Brookman-Amissah S, Kendel F, Spivak I, Pflanz S, Roigas J, Klotz T, May M: Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. BJU Int 2009;103:1375-1380.
21.
de Cássio Zequi S, de Campos ECR, Guimarães GC, Bachega W Jr, da Fonseca FP, Lopes A: The use of the American Society of Anesthesiology classification as a prognostic factor in patients with renal cell carcinoma. Urol Int 2010;84:67-72.
22.
Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-1657.
23.
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-4566.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.